NCT03237780 2026-04-13
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT03775265 2026-04-13
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04138628 2026-04-07
TOMBOLA
Aarhus University Hospital
Phase 2 Active not recruiting
NCT04630730 2026-01-21
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT02989584 2026-01-07
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03697850 2025-11-18
BladderSpar
UNICANCER
Phase 2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03799835 2024-12-11
ALBAN
UNICANCER
Phase 3 Active not recruiting
NCT04289779 2024-12-04
ABATE
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT04134000 2024-05-21
BladderGATE
Fundacion Oncosur
Phase 1 Active not recruiting
NCT04186013 2022-10-26
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
Spanish Oncology Genito-Urinary Group
Phase 2 Active not recruiting
NCT03179943 2021-11-04
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting